The Ventritex(R) Cadence(R) Model V-100 Tiered Therapy Defibrillator i
s a third generation antitachyarrhythmia device currently completing c
linical trials in the United States. The implantable pulse generator i
s capable of high energy defibrillation, low energy cardioversion, as
well as antitachycardia and bradycardia pacing. In addition, this micr
oprocessor controlled device can deliver monophasic or biphasic defibr
illation/cardioversion shocks, is noncommitted to deliver shock therap
y after initiating charging for defibrillation or cardioversion therap
y, and can store electrograms of spontaneous tachyarrhythmia episodes.
These expanded device capabilities should improve therapy efficacy an
d patient management, and represent a major advance in the treatment o
f patients with ventricular tachyarrhythmias.